Rapid effects of zoledronic acid in reducing bone complications in patients with bone metastases in the first 3 months of treatment

被引：0
|
作者：
Saad, F.
Chen, Y. M.
机构：
[1] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[2] Novartis Oncol, E Hanover, NJ USA
来源：
CANCER TREATMENT REVIEWS | 2006年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
131
引用
下载
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [21] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Altundag, M. K.
    Dincer, M.
    Harputluoglu, H.
    Aksoy, S.
    Ozisik, Y.
    Guler, N.
    Tekuzman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases
    Dincer, Murat
    Altundag, Kadri
    Harputluoglu, Hakan
    Aksoy, Sercan
    Cengiz, Mustafa
    Gullu, Ibrahim
    MEDICAL ONCOLOGY, 2008, 25 (03) : 356 - 359
  • [23] Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid
    Aapro, Matti
    Saad, Fred
    THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (02) : 85 - 101
  • [24] Zoledronic acid for the treatment of bone Metastases in patients with breast cancer and other solid tumors
    Lacerna, L
    Hohneker, J
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 150 - 160
  • [25] Denosumab and zoledronic acid (ZA) treatment in patients with genitourinary (GU) cancers and bone metastases
    Ganju, Vinod
    Costa, Luis
    Fizazi, Karim
    Saad, Fred
    Brown, Janet
    von Moos, Roger
    Oudard, Stephane
    Sternberg, Cora N.
    Miller, Kurt
    Wang, Huei
    Maniar, Tap
    Braun, Ada
    BJU INTERNATIONAL, 2013, 112 : 11 - 11
  • [26] Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases
    Feng Wang
    Wei Chen
    Hongde Chen
    Licai Mo
    Haiyong Jin
    Zhixian Yu
    Chengdi Li
    Qing Liu
    Feifei Duan
    Zhiliang Weng
    Medical Oncology, 2013, 30
  • [27] Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases
    Wang, Feng
    Chen, Wei
    Chen, Hongde
    Mo, Licai
    Jin, Haiyong
    Yu, Zhixian
    Li, Chengdi
    Liu, Qing
    Duan, Feifei
    Weng, Zhiliang
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [28] Zoledronic acid reduces bone resorption markers in patients with lytic and blastic bone metastases
    Saad, F
    Gleason, D
    Rosen, L
    Gordon, D
    BONE, 2002, 30 (03) : 53S - 53S
  • [29] Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Pectasides, D
    Nikolaou, M
    Farmakis, D
    Kanakis, I
    Gaglia, A
    Kountourakis, P
    Karamanos, NK
    Economopoulos, T
    Raptis, SA
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1457 - 1463
  • [30] Effects of zoledronic acid on serum levels of MMPs and bone remodeling markers in breast cancer patients with bone metastases
    Kanakis, I
    Nikolaou, M
    Kiamouris, C
    Pectasides, D
    Karamanos, N
    FEBS JOURNAL, 2005, 272 : 270 - 270
12345